Click on headlines below to download research

Leukaemia pipeline advances with new data
Hybrigenics | 24/05/2018

Hybrigenics has published data from a Phase II study in chronic myeloid leukaemia (CML). After one year of treatment, 40% of patients showed improvements…

Inecalcitol advancing towards data
Hybrigenics | 31/01/2018

Hybrigenics’ main value driver is inecalcitol. A Phase II study in chronic myeloid leukaemia (CML) is on track to complete in H218. Interim analysis…